Decitabine in the treatment of acute myeloid leukemia in elderly patients

References

• National Cancer InstituteSEER stat fact sheets: acute myeloid leukemia Available from: http://seer.cancer.gov/statfacts/html/amyl.htmlAccessed June 16, 2013
   Google Scholar
• MedeirosBCOthusMFangMRoulstonDAppelbaumFRPrognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experienceBlood2010116132224222820562328
   PubMed Web of Science ®Google Scholar
• GrimwadeDWalkerHHarrisonGThe predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood20019851312132011520776
   PubMed Web of Science ®Google Scholar
• BacherUKernWSchnittgerSHiddemannWHaferlachTSchochCPopulation-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemiaHaematologica200590111502151016266897
   PubMed Web of Science ®Google Scholar
• SchneiderFHosterESchneiderSAge-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)Ann Hematol201291191821744003
   PubMed Web of Science ®Google Scholar
• LeithCPKopeckyKJGodwinJAcute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group studyBlood1997899332333299129038
   PubMed Web of Science ®Google Scholar
• StresemannCLykoFModes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInt J Cancer2008123181318425818
   PubMed Web of Science ®Google Scholar
• ChristmanJK5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene200221355483549512154409
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol200220102429244012011120
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
   PubMed Web of Science ®Google Scholar
• LöwenbergBOssenkoppeleGJvan PuttenWHigh-dose daunorubicin in older patients with acute myeloid leukemiaN Engl J Med2009361131235124819776405
   PubMed Web of Science ®Google Scholar
• TillyHCastaigneSBordessouleDLow-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderlyJ Clin Oncol1990822722792299370
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSCortesJResults of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeCancer200610651090109816435386
   PubMed Web of Science ®Google Scholar
• OranBWeisdorfDJSurvival for older patients with acute myeloid leukemia: a population-based studyHaematologica201297121916192422773600
   PubMed Web of Science ®Google Scholar
• RoweJMNeubergDFriedenbergWA phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupBlood2004103247948514512295
   PubMed Web of Science ®Google Scholar
• EsteyEde LimaMTibesRProspective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)Blood200710941395140017038533
   PubMed Web of Science ®Google Scholar
• MenzinJLangKEarleCCKerneyDMallickRThe outcomes and costs of acute myeloid leukemia among the elderlyArch Inter Med20021621415971603
   PubMed Web of Science ®Google Scholar
• BurnettAKMilliganDPrenticeAGA comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer200710961114112417315155
   PubMed Web of Science ®Google Scholar
• CastaigneSPautasCTerreCEffect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyLancet201237998251508151622482940
   PubMed Web of Science ®Google Scholar
• PetersdorfSHKopeckyKJSlovakMA phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaBlood2013121244854486023591789
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology version 2.2013: acute myeloid leukemia Available from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdfAccessed June 16, 2013
   Google Scholar
• TranHYangDClofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adultsAnn Pharmacother2012461899622170975
   PubMed Web of Science ®Google Scholar
• KeatingGMAzacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemiaDrugs20127281111113622571445
   PubMed Web of Science ®Google Scholar
• MomparlerRLMomparlerLFSamsonJComparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemiaLeuk Res198486104310496083417
   PubMed Web of Science ®Google Scholar
• PettiMCMandelliFZagonelVPilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary resultsLeukemia19937Suppl 136417683355
   PubMed Web of Science ®Google Scholar
• WillemzeRSuciuSArchimbaudEA randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)Leukemia199711Suppl 1S24S279130688
   PubMed Web of Science ®Google Scholar
• JonesPATaylorSMCellular differentiation, cytidine analogs and DNA methylationCell198020185936156004
   PubMed Web of Science ®Google Scholar
• MomparlerRLPharmacology of 5-Aza-2′-deoxycytidine (decitabine)Semin Hematol2005423 Suppl 2S9S1616015507
   PubMed Web of Science ®Google Scholar
• BaylinSBDNA methylation and gene silencing in cancerNat Clin Pract Oncology20052Suppl 1S4S11
   PubMedGoogle Scholar
• HermanJGBaylinSBGene silencing in cancer in association with promoter hypermethylationN Engl J Med2003349212042205414627790
   PubMed Web of Science ®Google Scholar
• LeoneGTeofiliLVosoMTLübbertMDNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemiasHaematologica200287121324134112495905
   PubMed Web of Science ®Google Scholar
• SchoofsTMüller-TidowCDNA methylation as a pathogenic event and as a therapeutic target in AMLCancer Treat Rev201137Suppl 1S13S1821612874
   PubMed Web of Science ®Google Scholar
• AgrawalSHofmannWKTidowNThe C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemiaBlood200710993895390517234736
   PubMed Web of Science ®Google Scholar
• LübbertMSuciuSBailaLLow-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelo-dysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupJ Clin Oncol201129151987199621483003
   PubMed Web of Science ®Google Scholar
• IssaJPGarcia-ManeroGGilesFJPhase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood200410351635164014604977
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGKantarjianHMSanchez-GonzalezBPhase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood2006108103271327916882711
   PubMed Web of Science ®Google Scholar
• BlumWKlisovicRBHackansonBPhase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaJ Clin Oncol200725253884389117679729
   PubMed Web of Science ®Google Scholar
• CashenAFSchillerGJO’DonnellMRDiPersioJFMulticenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaJ Clin Oncol201028455656120026803
   PubMed Web of Science ®Google Scholar
• KantarjianHOkiYGarcia-ManeroGResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood20071091525716882708
   PubMed Web of Science ®Google Scholar
• SteensmaDPBaerMRSlackJLMulticenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialJ Clin Oncol200927233842384819528372
   PubMed Web of Science ®Google Scholar
• BlumWGarzonRKlisovicRBClinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProc Natl Acad Sci U S A2010107167473747820368434
   PubMed Web of Science ®Google Scholar
• LübbertMRüterBHClausRA multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyHaematologica201297339340122058219
   PubMed Web of Science ®Google Scholar
• KantarjianHMThomasXGDmoszynskaAMulticenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaJ Clin Oncol201230212670267722689805
   PubMed Web of Science ®Google Scholar
• SekeresMASteensmaDPBoulevard of broken dreams: drug approval for older adults with acute myeloid leukemiaJ Clin Oncol201230334061406323008302
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEAzacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaJ Clin Oncol201028456256920026804
   PubMed Web of Science ®Google Scholar
• KantarjianHWilsonWRavandiFEsteyEDecitabine in older adults with acute myeloid leukemia: why was the dream broken?J Clin Oncol201331141795179623547076
   PubMed Web of Science ®Google Scholar
• RavandiFIssaJPGarcia-ManeroGSuperior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalitiesCancer2009115245746575119795507
   PubMed Web of Science ®Google Scholar
• FurlanIBatzCFlothoCIntriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7Blood2009113122867286819299654
   PubMed Web of Science ®Google Scholar
• RüterBWijermansPClausRKunzmannRLübbertMPreferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7Blood2007110310801082 author reply 108317644749
   PubMed Web of Science ®Google Scholar
• LübbertMBertzHRüterBNon-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patientsBone Marrow Transplant200944958558819363531
   PubMed Web of Science ®Google Scholar
• LübbertMBertzHMüllerMJFinkeJWhen azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemiaJ Clin Oncol201331682282323129745
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [website on the Internet] Available from: http://www.clinicaltrials.govAccessed June 16, 2013
   Google Scholar
• KalacMScottoLMarchiEHDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLBlood2011118205506551621772049
   PubMed Web of Science ®Google Scholar
• MetzelerKHWalkerAGeyerSDNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemiaLeukemia20122651106110722124213
   PubMed Web of Science ®Google Scholar
• LavelleDVaitkusKLingYEffects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineBlood201211951240124722160381
   PubMed Web of Science ®Google Scholar